Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Director departure
Inv. presentation
Quarterly results
Appointed director

ARGOS THERAPEUTICS INC (ARGS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/03/2019 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from PricewaterhouseCoopers LLP to the SEC, regarding the statements made in this Current Report on Form 8-K"
12/03/2018 8-K Resignation/termination of a director
07/20/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/24/2018 8-K Quarterly results
04/19/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives - Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB Venture Market - DURHAM, N.C., April 19, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastat..."
04/02/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights DURHAM, NC, April 02, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today reported financial results and operational highlights for the fourth quarter and full year 2017. Jeff Abbey, CEO of Argos Therapeutics, stated, "Although we faced a very challenging 2017, we have been able to continue the Phase 3 ADAPT clinical trial of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and look forward to the next interim data analysis, which we expect to occur during the second quarter of 2018. In addition to cont..."
03/07/2018 8-K Other Events
02/16/2018 8-K Quarterly results
02/05/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Amended and Restated Sales Agreement, by and between the Company and Cowen and Company, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb. 05, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has entered into an option agreement with Pharmstandard International, S.A. and Actigen Limited under which the Company has an option to license a group of fully human anti-PD1 monoclonal antibodies and related technology. Results of a preclinic..."
01/30/2018 8-K/A Financial Statements and Exhibits
Docs: "Certificate of Amendment to Restated Certificate of Incorporation of Argos Therapeutics, Inc. (filed with the Secretary of State of the State of Delaware on January 18, 2018)"
01/18/2018 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
01/08/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Argos Announces $1.5 Million Equity Investment by Lummy , Ltd. DURHAM, N.C., Jan. 08, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has signed a stock purchase agreement with Lummy , Ltd. , the Company’s partner for Rocapuldencel-T in China and certain other territories, under which the Company has agreed to issue and sell to Lummy in a private financing 7.5 million shares of the Company’s common stock for an aggregate purchase price of $1.5 million. The sale of the shares is expected to close on or prior to March 7, 2018. Lummy has agreed that, on the closing date, it will execute and deliver a lockup a..."
11/28/2017 8-K Asset disposition
Docs: "Satisfaction and Release Agreement, by and between the Company and Saint-Gobain Performance Plastics Corporation, including a form of the Convertible Unsecured Promissory Note to be issued by the Company",
"Registration Rights Agreement, by and between the Company and Saint-Gobain Performance Plastics Corporation",
"Argos Provides Financial Update DURHAM, N.C., Nov. 28, 2017 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that TKC Properties, the landlord of the facility in Durham County, NC that Argos had previously intended to utilize as its primary manufacturing facility , has, with Argos’ full consent, successfully completed the sale of this facility to a third party. In connection with this transaction, Argos has entered into a lease termination agreement with TKC pursuant to which Argos received cash proceeds of approximately $1.8 million. Additionally, Argos is no longer required to maintain restricted cash of approximately..."
11/09/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/06/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/27/2017 8-K Quarterly results
09/26/2017 8-K Quarterly results
09/25/2017 8-K Quarterly results
09/12/2017 8-K Quarterly results
09/05/2017 8-K Quarterly results
08/02/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Argos Therapeutics, Inc. 2014 Stock Incentive Plan, as amended"
06/16/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
04/18/2017 8-K Form 8-K - Current report
04/13/2017 8-K Other Events
04/04/2017 8-K Form 8-K - Current report
03/23/2017 8-K Termination of a Material Definitive Agreement
03/09/2017 8-K Form 8-K - Current report
03/06/2017 8-K Form 8-K - Current report
02/22/2017 8-K Form 8-K - Current report
01/23/2017 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University"
12/15/2016 8-K Form 8-K - Current report
11/14/2016 8-K Quarterly results
Docs: "Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights"
08/10/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy